• Molecular NameMoclobemide
  • Synonym4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclaime; Moclamide; Moclamine; Moclobemid; Moclobemida [INN-Spanish]; moclobemide; Moclobemide [Usan:Ban:Inn]; Moclobemidum [INN-Latin]; p-Chloro-N-(2-morpholinoethyl)benzamide
  • Weight268.744
  • Drugbank_IDDB01171
  • ACS_NO71320-77-9
  • Show 3D model
  • LogP (experiment)1.298
  • LogP (predicted, AB/LogP v2.0)1.89
  • pka6.2
  • LogD (pH=7, predicted)1.86
  • Solubility (experiment)3.97 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.28
  • LogSw (predicted, AB/LogsW2.0)3.45
  • Sw (mg/ml) (predicted, ACD/Labs)9.82
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds4
  • TPSA41.57
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug primarily used to treat depression and social anxiety.
  • Absorption_value88.0
  • Absorption (description)Moclobemide is rapidly absorbed. Peak plasma levels occur 0.3 to 2 hours after oral administration. The bioavailability increases during the first week of therapy from 60% to 80% and more.
  • Caco_2N/A
  • Bioavailability75.0
  • Protein binding50.0
  • Volume of distribution (VD)1.2 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe drug is almost completely metabolized in the liver by 3 enzymes, CYP2C19, CYP2D6 and CYP1A2. The main metabolites are the N-oxide Ro 12-5637 and lactam derivative Ro 12-8095;
  • Half life1~4 h
  • ExcretionThe unchanged drug (less than 1%) as well as the metabolites are excreted renally (in urine).
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAcute Toxicity: The oral LD50-values in mouse and rat are quite high, indicating a wide therapeutic index. LD50 (mouse) is 730 mg/kg and LD50 (rat) is 1,300 mg/kg. In dogs doses in excess of 300 mg/kg led to vomiting, salivation, ataxia, and drowsiness. Chronic Toxicity: In an 18-months-study in rats with 10 mg/kg no signs of chronic toxicity were noted, with 50 mg/kg and 250 mg/kg only a slight loss of weight, and with 250 mg/kg mildly elevated Alkaline phosphatase and Gamma-GT. Studies in dogs revealed no toxicity relevant for humans. No evidence for a possible hepatic or cardiovascular toxicity was found.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=20.31 (ip)